Skip to content
lifestyle.clientim.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Quoin Pharmaceuticals, Inc.
CORRECTION — Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
September 8, 2026
Quoin Pharmaceuticals: QRX003 Receives FDA Rare Pediatric Disease Designation
September 8, 2026
Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
August 28, 2026
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
August 28, 2026
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 14, 2026
Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026
August 7, 2026
Quoin Pharmaceuticals Announces Japan’s MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
June 4, 2026
Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
June 2, 2026
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 7, 2026
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026
April 30, 2026
1
2
Next Page
→